Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome.
Schramm, Elizabeth C; Roumenina, Lubka T; Rybkine, Tania; Chauvet, Sophie; Vieira-Martins, Paula; Hue, Christophe; Maga, Tara; Valoti, Elisabetta; Wilson, Valerie; Jokiranta, Sakari; Smith, Richard J H; Noris, Marina; Goodship, Tim; Atkinson, John P; Fremeaux-Bacchi, Veronique.
; 125(15): 2359-69, 2015 Apr 09.
Artigo em Inglês | MEDLINE | ID: mdl-25608561
Mutations in complement C3 from aHUS patients.
Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.
aHUS associated with C3 gene mutation: a case with numerous relapses and favorable 20-year outcome.
Disease Recurrence After Early Discontinuation of Eculizumab in a Patient With Atypical Hemolytic Uremic Syndrome With Complement C3 I1157T Mutation.
A novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomerulopathy.
Macrovascular involvement in a child with atypical hemolytic uremic syndrome.
C3:CH50 ratio as a proposed composite marker for eculizumab monitoring in atypical hemolytic uremic syndrome: Preliminary results.
Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Prevention of recurrence of atypical hemolytic uremic syndrome post renal transplant with the use of higher-dose eculizumabâ©.
The development of atypical hemolytic uremic syndrome depends on complement C5.